It is a dimeric complex composed of: The calcitonin receptor (CTR) , a GPCR The RAMP protein (Receptor Activity Modifying Protein), 1, 2 or 3 Depending on the type of RAMP, three different amylin receptors arise: AMY1 : CTR + RAMP1, primarily in the CNS (area postrema, hypothalamus) AMY2 : CTR + RAMP2, peripheral tissues AMY3 : CTR + RAMP3, bone tissue, some CNS Cagrilintide activates all three amylin receptors , but the primary therapeutic effect is via AMY1 in the area postrema (brainstem, where nausea and satiety signals are processed)
Then the rules changed
Research-chemical identity
The frequency of your treatment is entirely dependent on your bodys individual needs
Animal data is labelled as such and never presented as equivalent to human trial data
Elderly patients (75+ years) Considerations: Multiple medications increasing interaction risks, reduced kidney/liver function affecting peptide clearance, fragile vessels increasing injection bruising, cognitive changes potentially affecting protocol adherence, fixed incomes limiting expensive interventions
